Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Sept. 30, 2024. Highlights and Outlook ...

Transscatheter aortic valve replacement is a novel way ... [33] There have been three generations of the Cribier-Edwards SAPIEN valve. The only valve that has FDA approval is the Edwards SAPIEN ...

Transcatheter Aortic Valve Implantation: Current & Future Devices To date, most clinical experience has been gathered using the Edwards Sapien™ and the CoreValve™ systems, both of which have ...

Also anticipated is the PROGRESS trial, which is looking at the newer-generation Sapien valves in moderate aortic stenosis, ...

Notably, the landmark multicenter study focused on aortic valve outcomes in patients with Marfan syndrome has resulted in several publications and will continue through 2030. Using large publicly ...

Edwards Lifesciences today announced the launch in Europe of the SAPIEN 3 transcatheter pulmonary valve implantation (TPVI) system with Alterra adaptive prestent, expanding minimally invasive ...

The outcome revealed that Edwards SAPIEN 3 or SAPIEN 3 Ultra valves have led to superior outcomes for women compared with ...

James PORTICO Re-Sheathable Transcatheter Aortic Valve System (Sponsor's Protocol CL06799) – PI: Davies, James A Prospective, Randomized, Controlled, Multi-Center, Study to Establish the Safety and ...

As your heart beats, it pumps blood from the left ventricle through the aortic valve and into the aorta, your body’s largest artery. The aortic valve is made up of three triangular flaps of ...

EW is likely to have witnessed continued growth in TAVR procedures across the United States and worldwide in the third ...

Innovations such as the RESILLIA technology enhance the performance of the company’s TAVR (Transcatheter Aortic Valve ... quarter driven by the SAPIEN 3 Ultra RESILIA valve.